Annual SGA
$10.30 M
-$10.41 M-50.27%
December 31, 2023
Summary
- As of February 8, 2025, AVTX annual SGA is $10.30 million, with the most recent change of -$10.41 million (-50.27%) on December 31, 2023.
- During the last 3 years, AVTX annual SGA has fallen by -$9.46 million (-47.87%).
- AVTX annual SGA is now -58.23% below its all-time high of $24.66 million, reached on December 31, 2021.
Performance
AVTX SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$4.29 M
-$242.00 K-5.34%
September 30, 2024
Summary
- As of February 8, 2025, AVTX quarterly SGA is $4.29 million, with the most recent change of -$242.00 thousand (-5.34%) on September 30, 2024.
- Over the past year, AVTX quarterly SGA has dropped by -$242.00 thousand (-5.34%).
- AVTX quarterly SGA is now -63.32% below its all-time high of $11.68 million, reached on March 31, 2022.
Performance
AVTX Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$1.48 B
-$7.96 M-0.54%
September 30, 2024
Summary
- As of February 8, 2025, AVTX TTM SGA is -$1.48 billion, with the most recent change of -$7.96 million (-0.54%) on September 30, 2024.
- Over the past year, AVTX TTM SGA has dropped by -$1.50 billion (-11618.92%).
- AVTX TTM SGA is now -3346.31% below its all-time high of -$43.07 million.
Performance
AVTX TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
AVTX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -50.3% | -5.3% | -10000.0% |
| 3 y3 years | -47.9% | +44.9% | -7267.4% |
| 5 y5 years | -6.8% | +50.3% | -7267.4% |
AVTX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -58.2% | at low | -63.3% | +76.6% | -58.1% | at low |
| 5 y | 5-year | -58.2% | at low | -63.3% | +76.6% | -231.5% | at low |
| alltime | all time | -58.2% | +156.2% | -63.3% | +260.8% | -3346.3% | at low |
Avalo Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $4.29 M(-5.3%) | $14.68 M(+13.9%) |
| Jun 2024 | - | $4.53 M(+41.8%) | $12.89 M(+19.5%) |
| Mar 2024 | - | $3.19 M(+19.3%) | $10.79 M(+4.7%) |
| Dec 2023 | $10.30 M(-50.3%) | $2.68 M(+7.5%) | $10.30 M(-2.7%) |
| Sep 2023 | - | $2.49 M(+2.6%) | $10.58 M(-7.0%) |
| Jun 2023 | - | $2.43 M(-10.4%) | $11.38 M(-3.0%) |
| Mar 2023 | - | $2.71 M(-8.5%) | $11.73 M(-43.3%) |
| Dec 2022 | $20.71 M(-16.0%) | $2.96 M(-9.9%) | $20.71 M(-12.7%) |
| Sep 2022 | - | $3.28 M(+18.0%) | $23.73 M(-10.0%) |
| Jun 2022 | - | $2.78 M(-76.2%) | $26.38 M(-14.9%) |
| Mar 2022 | - | $11.68 M(+95.4%) | $31.00 M(+25.7%) |
| Dec 2021 | $24.66 M(+24.8%) | $5.98 M(+0.9%) | $24.66 M(+5.9%) |
| Sep 2021 | - | $5.93 M(-20.0%) | $23.29 M(+4.0%) |
| Jun 2021 | - | $7.40 M(+38.5%) | $22.40 M(+3.0%) |
| Mar 2021 | - | $5.35 M(+15.8%) | $21.75 M(+10.1%) |
| Dec 2020 | $19.76 M(+70.2%) | $4.62 M(-8.3%) | $19.76 M(+8.8%) |
| Sep 2020 | - | $5.04 M(-25.5%) | $18.16 M(+13.7%) |
| Jun 2020 | - | $6.75 M(+101.4%) | $15.98 M(+34.4%) |
| Mar 2020 | - | $3.35 M(+11.1%) | $11.89 M(+2.4%) |
| Dec 2019 | $11.61 M | $3.02 M(+5.8%) | $11.61 M(+95.9%) |
| Sep 2019 | - | $2.85 M(+6.9%) | $5.93 M(-18.5%) |
| Jun 2019 | - | $2.67 M(-13.2%) | $7.27 M(-25.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $3.07 M(-215.2%) | $9.69 M(-12.4%) |
| Dec 2018 | $11.06 M(+29.9%) | -$2.67 M(-163.6%) | $11.06 M(-36.1%) |
| Sep 2018 | - | $4.20 M(-17.5%) | $17.31 M(+13.4%) |
| Jun 2018 | - | $5.08 M(+14.4%) | $15.27 M(+31.4%) |
| Mar 2018 | - | $4.44 M(+23.8%) | $11.62 M(+36.6%) |
| Dec 2017 | $8.51 M(+20.2%) | $3.59 M(+66.8%) | $8.51 M(+41.5%) |
| Sep 2017 | - | $2.15 M(+49.5%) | $6.02 M(+8.1%) |
| Jun 2017 | - | $1.44 M(+8.2%) | $5.57 M(-3.4%) |
| Mar 2017 | - | $1.33 M(+21.6%) | $5.76 M(-18.6%) |
| Dec 2016 | $7.08 M(+60.2%) | $1.09 M(-35.8%) | $7.08 M(-10.5%) |
| Sep 2016 | - | $1.70 M(+4.1%) | $7.91 M(+14.2%) |
| Jun 2016 | - | $1.64 M(-38.2%) | $6.93 M(+9.8%) |
| Mar 2016 | - | $2.65 M(+37.7%) | $6.31 M(+42.7%) |
| Dec 2015 | $4.42 M(-9.3%) | $1.92 M(+166.6%) | $4.42 M(+8.6%) |
| Sep 2015 | - | $721.70 K(-29.0%) | $4.07 M(-18.2%) |
| Jun 2015 | - | $1.02 M(+33.6%) | $4.98 M(+4.7%) |
| Mar 2015 | - | $760.80 K(-51.7%) | $4.76 M(-2.4%) |
| Dec 2014 | $4.88 M(+21.3%) | $1.57 M(-3.3%) | $4.88 M(+47.7%) |
| Sep 2014 | - | $1.63 M(+104.8%) | $3.30 M(+97.2%) |
| Jun 2014 | - | $794.50 K(-9.6%) | $1.67 M(+90.4%) |
| Mar 2014 | - | $879.10 K | $879.10 K |
| Dec 2013 | $4.02 M | - | - |
FAQ
- What is Avalo Therapeutics annual SGA?
- What is the all time high annual SGA for Avalo Therapeutics?
- What is Avalo Therapeutics annual SGA year-on-year change?
- What is Avalo Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Avalo Therapeutics?
- What is Avalo Therapeutics quarterly SGA year-on-year change?
- What is Avalo Therapeutics TTM SGA?
- What is the all time high TTM SGA for Avalo Therapeutics?
- What is Avalo Therapeutics TTM SGA year-on-year change?
What is Avalo Therapeutics annual SGA?
The current annual SGA of AVTX is $10.30 M
What is the all time high annual SGA for Avalo Therapeutics?
Avalo Therapeutics all-time high annual SGA is $24.66 M
What is Avalo Therapeutics annual SGA year-on-year change?
Over the past year, AVTX annual SGA has changed by -$10.41 M (-50.27%)
What is Avalo Therapeutics quarterly SGA?
The current quarterly SGA of AVTX is $4.29 M
What is the all time high quarterly SGA for Avalo Therapeutics?
Avalo Therapeutics all-time high quarterly SGA is $11.68 M
What is Avalo Therapeutics quarterly SGA year-on-year change?
Over the past year, AVTX quarterly SGA has changed by -$242.00 K (-5.34%)
What is Avalo Therapeutics TTM SGA?
The current TTM SGA of AVTX is -$1.48 B
What is the all time high TTM SGA for Avalo Therapeutics?
Avalo Therapeutics all-time high TTM SGA is -$43.07 M
What is Avalo Therapeutics TTM SGA year-on-year change?
Over the past year, AVTX TTM SGA has changed by -$1.50 B (-11618.92%)